272 completed, 64 terminated, 20 recruiting, 19 active not recruiting. 403 Phase 1, 88 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 1 | 403 | Completed 272, Terminated 64, Recruiting 20, Active not recruiting 19, Withdrawn 14, Unknown 8, Not yet recruiting 5, Suspended 1 |
| Phase 2 | 88 | Completed 47, Terminated 17, Active not recruiting 8, Withdrawn 7, Recruiting 4, Unknown 4, Not yet recruiting 1 |
Follow Amgen: new trials by email
Trials (filtered) newest first · largest first
All 403 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | 20 | 2026-11-18 | 2026-08-12 |
Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation
Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic | Phase 1 | Not yet recruiting | 114 | 2026-11-18 | 2026-11-02 |
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Recruiting | 180 | 2026-11-13 | 2026-11-02 |
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Not yet recruiting | 356 | 2026-11-09 | 2026-11-06 |
Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Maridebart Cafraglutide - Overweight, Obesity | Phase 1 | Not yet recruiting | 340 | 2026-10-12 | 2026-09-22 |
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Romosozumab - Healthy Participants | Phase 1 | Recruiting | 308 | 2026-09-22 | 2026-10-13 |
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | 26 | 2026-09-01 | 2026-08-11 |
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
AMG 691 - Healthy Participants | Phase 1 | Recruiting | 28 | 2026-08-07 | 2026-10-28 |
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
AMG 127, Placebo - Diabetes Mellitus, Type 2 | Phase 1 | Recruiting | 162 | 2026-06-11 | 2026-08-03 |
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Xaluritamig - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | 40 | 2026-04-28 | 2026-09-15 |
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
ZL-1310, Tarlatamab, Durvalumab - Small Cell Lung Cancer | Phase 1 | Recruiting | 160 | 2026-04-21 | 2026-08-21 |
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference) - Healthy Participants | Phase 1 | Completed | 405 | 2026-04-21 | 2026-10-02 |
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
COC, Maridebart Cafraglutide - Overweight, Obesity | Phase 1 | Active not recruiting | 49 | 2026-04-09 | 2026-07-20 |
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
AMG 436 - Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | Phase 1 | Recruiting | 464 | 2026-04-08 | 2026-10-20 |
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Xaluritamig - Ewing Sarcoma | Phase 1 | Recruiting | 50 | 2026-04-08 | 2026-10-29 |
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | 10 | 2026-02-01 | 2026-05-08 |
A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | 3 | 2026-01-30 | 2026-08-18 |
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Evolocumab Drug Substance A, Evolocumab Drug Substance B - Healthy Participants, Pharmacokinetics | Phase 1 | Completed | 405 | 2026-01-16 | 2026-08-17 |
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
Maridebart Cafraglutide - Overweight and Obesity | Phase 1 | Completed | 349 | 2025-12-15 | 2026-08-07 |
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | 104 | 2025-12-08 | 2026-10-05 |
Showing 20 of 403. Sign in to see all of them.
Conditions studied
Neoplasms (37) · Multiple Myeloma (31) · Carcinoma, Non-Small-Cell Lung (17) · Obesity (17) · Lupus Erythematosus, Systemic (15) · Recurrence (15) · Overweight (13) · Neoplasm Metastasis (12) · Colorectal Neoplasms (11) · Asthma (10) · Lymphoma (10) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Non-Hodgkin (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Breast Neoplasms (9)
Interventions
carfilzomib (33) · Dexamethasone (29) · sotorasib (25) · Panitumumab (16) · blinatumomab (16) · talimogene laherparepvec (15) · Carboplatin (14) · Paclitaxel (14) · pembrolizumab (13) · trebananib (11) · Calcium Dobesilate (10) · motesanib diphosphate (10) · Cyclophosphamide (9) · Denosumab (8) · Etanercept (8)
Countries
United States (296) · Australia (66) · Germany (46) · Spain (44) · France (43) · Canada (41) · Belgium (40) · Japan (40) · United Kingdom (29) · Netherlands (28) · South Korea (25) · Taiwan (21) · Poland (20) · Italy (19) · Austria (18)
Top investigators
Brian GM Durie, MD (3) · Jatin Shah, MD (2) · John Rieth, MD (2) · Saroj Vadhan-Raj, MD (2) · Abby Siegel, MD, MS (1) · Adam Cohen, MD (1) · Ahmad Tarhini, MD (1) · Allen R. Chen, MD, PhD, MHS (1) · Amanda Townsend, MBBS (1) · Amy J Chien, MD (1) · Amy Kimball, MD (1)
Results publications
PMID 39604046, PMID 20512995, PMID 21917874, PMID 26138472, PMID 26290435, PMID 26449617, PMID 27099766, PMID 33051459, PMID 35820631, PMID 41036707, PMID 12675312, PMID 12957457, PMID 13680158, PMID 15173079, PMID 16200343, PMID 16530701, PMID 16786120, PMID 16899365, PMID 17557949, PMID 17664336, PMID 17705175, PMID 17896890, PMID 18509186, PMID 19074216, PMID 19203894, PMID 19221744, PMID 19366957, PMID 20167817, PMID 20603435, PMID 20703446, PMID 20838435, PMID 21147753, PMID 21150307, PMID 21327941, PMID 21633906, PMID 21660636, PMID 21688301, PMID 21791058, PMID 22210018, PMID 22665268, PMID 22872523, PMID 23193213, PMID 23243055, PMID 23370314, PMID 23447001, PMID 23504398, PMID 23679351, PMID 24014245, PMID 24286136, PMID 24429497
NIH funding
2017 (8), 2014 (7), 2023 (7), 2015 (6), 2018 (5), 2016 (2), 2025 (2), 2009 (1), 2019 (1), M01RR001032 (1), P30CA036727 (1), P50CA136411 (1), R01CA136907 (1), R01DK058785 (1), R01NS049639 (1)